Morel CM - Search Results

1

Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.

Morel CM, Lindahl O, Harbarth S, de Kraker MEA, Edwards S, Hollis A. Morel CM, et al. J Antibiot (Tokyo). 2020 Jul;73(7):421-428. doi: 10.1038/s41429-020-0300-y. Epub 2020 Mar 19. J Antibiot (Tokyo). 2020. PMID: 32203126 Free PMC article. Review.

2

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective.

von Dach E, Morel CM, Murthy A, Pagani L, Macedo-Vinas M, Olearo F, Harbarth S. von Dach E, et al. Among authors: morel cm. Clin Microbiol Infect. 2017 Sep;23(9):659-666. doi: 10.1016/j.cmi.2017.02.011. Epub 2017 Feb 20. Clin Microbiol Infect. 2017. PMID: 28232163 Free article.

3

Human resources estimates and funding for antibiotic stewardship teams are urgently needed.

Pulcini C, Morel CM, Tacconelli E, Beovic B, de With K, Goossens H, Harbarth S, Holmes A, Howard P, Morris AM, Nathwani D, Sharland M, Schouten J, Thursky K, Laxminarayan R, Mendelson M. Pulcini C, et al. Among authors: morel cm. Clin Microbiol Infect. 2017 Nov;23(11):785-787. doi: 10.1016/j.cmi.2017.07.013. Epub 2017 Aug 2. Clin Microbiol Infect. 2017. PMID: 28778544 Free article. No abstract available.

4

Preserving the 'commons': addressing the sustainable use of antibiotics through an economic lens.

Morel CM, Edwards SE, Harbarth S. Morel CM, et al. Clin Microbiol Infect. 2017 Oct;23(10):718-722. doi: 10.1016/j.cmi.2017.08.002. Epub 2017 Aug 12. Clin Microbiol Infect. 2017. PMID: 28811243 Free article. Review.

5

Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.

Baraldi E, Ciabuschi F, Leach R, Morel CM, Waluszewski A. Baraldi E, et al. Among authors: morel cm. Am J Law Med. 2016 May;42(2-3):451-486. doi: 10.1177/0098858816658276. Am J Law Med. 2016. PMID: 29086643

6

Mapping global policy discourse on antimicrobial resistance.

Wernli D, Jørgensen PS, Morel CM, Carroll S, Harbarth S, Levrat N, Pittet D. Wernli D, et al. Among authors: morel cm. BMJ Glob Health. 2017 Jul 13;2(2):e000378. doi: 10.1136/bmjgh-2017-000378. eCollection 2017. BMJ Glob Health. 2017. PMID: 29225939 Free PMC article.

7

Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.

Morel CM, Edwards SE. Morel CM, et al. J Law Med Ethics. 2018 Jun;46(1_suppl):75-80. doi: 10.1177/1073110518782918. J Law Med Ethics. 2018. PMID: 30146962

8

Conflicts of interest in infection prevention and control research: no smoke without fire. A narrative review.

Abbas M, Pires D, Peters A, Morel CM, Hurst S, Holmes A, Saito H, Allegranzi B, Lucet JC, Zingg W, Harbarth S, Pittet D. Abbas M, et al. Among authors: morel cm. Intensive Care Med. 2018 Oct;44(10):1679-1690. doi: 10.1007/s00134-018-5361-z. Epub 2018 Sep 11. Intensive Care Med. 2018. PMID: 30206643 Review.

9

Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?

Edwards SE, Morel CM, Busse R, Harbarth S. Edwards SE, et al. Among authors: morel cm. Antibiotics (Basel). 2018 Dec 18;7(4):111. doi: 10.3390/antibiotics7040111. Antibiotics (Basel). 2018. PMID: 30567308 Free PMC article.

10

Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.

Edwards SE, Morel CM. Edwards SE, et al. Among authors: morel cm. Expert Rev Pharmacoecon Outcomes Res. 2019 Dec;19(6):685-692. doi: 10.1080/14737167.2019.1702523. Epub 2019 Dec 18. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 31847613 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

117 results

Search Page